RNAi

News

Sanofi and Alnylam conclude research phase of RNAi alliance

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.

News

Alnylam hopes for 2018 filing for RNAi liver disease drug

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<

News

Sanofi passes on Alnylam's breakthrough therapy

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.

Partner Content

Partner Content

Topics Presented this February 2018 at RNA Therapeutics

RNA Therapeutics 2018

News

Alnylam beats Ionis in RNA drug battle

Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen.

News